Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease

Mayo Clinic Proceedings

Volumn 89, Issue 5, 2014, Pages 615-622

  Hutchison, Colin A ^a   Burmeister, Anne ^b,c   Harding, Stephen J ^b,d   Basnayake, Kolitha ^e   Church, Hannah ^c   Jesky, Mark D ^c   White, Katie ^c   Green, Clara E ^c   Stringer, Stephanie J ^c,d   Bassett, Paul ^e   Ferro, Charles J ^c,d   Cockwell, Paul ^c,d  

^a Binding Site Group Ltd   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

^e Statsconsultancy Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYSTATIN C; IMMUNOGLOBULIN; POLYCLONAL IMMUNOGLOBULIN FREE LIGHT CHAIN; POLYCLONAL IMMUNOGLOBULIN FREE LIGHT CHAIN KAPPA; POLYCLONAL IMMUNOGLOBULIN FREE LIGHT CHAIN LAMBDA; UNCLASSIFIED DRUG;

ADULT; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ETHNICITY; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROTEIN BLOOD LEVEL; PYELONEPHRITIS; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TURBIDIMETRY;

BIOLOGICAL MARKERS; CAUSE OF DEATH; COMORBIDITY; ENGLAND; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84901496793     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.01.028     Document Type: Article

References (28)

1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease [published correction appears in Lancet. 2010;376(9736):162]. Lancet. 2010;375(9722): 1296-1309.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047. (Pubitemid 350074801)
3. Collins AJ, Chen SC, Gilbertson DT, Foley RN. CKD surveillance using administrative data: impact on the health care system. Am J Kidney Dis. 2009;53(3, suppl 3):S27-S36.
4. Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(suppl 3): iii73-iii80.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med. 2008;18(4):4]. N Engl J Med. 2004;351(13): 1296-1305.
6. Matsushita K, van der Velde M, Astor BC, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
7. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis. 2006;13(3):199-204. (Pubitemid 43947730)
8. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93-99. (Pubitemid 29313142)
9. Yilmaz MI, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. Clin Nephrol. 2007;68(1):1-9. (Pubitemid 47045486)
10. Dispenzieri A, Kyle R, Merlini G, et al; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-224.
11. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
12. Anandram S, Assi LK, Lovatt T, et al. Elevated, combined serum free light chain levels and increased mortality: a 5-year followup, UK study. J Clin Pathol. 2012;65(11):1036-1042.
13. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem. 2011;57(10):1387-1389.
14. Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009;114(24):4928-4932.
15. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773-779.
16. Haynes R, Hutchison CA, Emberson J, et al. Serum free light chains and the risk of ESRD and death in CKD. Clin J Am Soc Nephrol. 2011;6(12):2829-2837.
17. Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc. 2012;87(6): 517-523.
18. Aggarwal R, Sequeira W, Kokebie R, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken). 2011;63(6):891-898.
19. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100. (Pubitemid 41623371)
20. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ III. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004;79(7): 859-866. (Pubitemid 38879951)
21. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
22. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study [published correction appears in Lancet. 2010;376(9738): 332]. Lancet. 2010;375(9727):1721-1728.
23. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684-1690.
24. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9:11.
25. Durig J, Eisele L, Huttman A, Duhrsen U, Fuhrer A, Kieruzel S. Polyclonal free light chain evaluation and mortality in the German Heinz Nixdorf Recall Study. Hematol Rep. 2010;2(s2):13.
26. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest. 1991;64(4):527-537.
27. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:287-294.
28. Cohen G, Hörl WH. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin Dial. 2009; 22(4):369-372.